drug

INCB123667

1 story · latest Sep 1, 2026

Status: Investigational
Trials: 3 registered trials in coverage

Relationships

Developed by Incyte Corporation

Timeline

Incyte registers Phase 3 MAESTRA 3 trial in cyclin E1-overexpressing ovarian cancer

Sep 1Trial updateINCB123667 Incyte Corporation

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.